InMed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company. It engages in developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol in diseases with unmet medical need. InMed Pharmaceuticals Inc. is based in VANCOUVER, BC.
| Revenue (Most Recent Fiscal Year) | $4.94M |
| Net Income (Most Recent Fiscal Year) | $-8.16M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.78 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.32 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -171.13% |
| Net Margin (Trailing 12 Months) | -171.13% |
| Return on Equity (Trailing 12 Months) | -85.91% |
| Return on Assets (Trailing 12 Months) | -70.29% |
| Current Ratio (Most Recent Fiscal Quarter) | 6.95 |
| Quick Ratio (Most Recent Fiscal Quarter) | 6.37 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.02 |
| Inventory Turnover (Trailing 12 Months) | 3.38 |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.71 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 2.80M |
| Free Float | 2.78M |
| Market Capitalization | $3.76M |
| Average Volume (Last 20 Days) | 0.86M |
| Beta (Past 60 Months) | 0.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.85% |
| Percentage Held By Institutions (Latest 13F Reports) | 20.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |